Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors
about
A Case of Painless Legs and Moving Toes Syndrome in Parkinson's Disease Responsive to Dopaminergic Therapy.Targeting the dopamine D3 receptor: an overview of drug design strategies.Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.Different effects of rotigotine and ropinirole on cholinergic transmission in the mouse medial prefrontal cortex.Targeting hypersensitive corticostriatal terminals in restless legs syndrome.Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease.Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson's Disease Patients Taking Dopaminergic Medication.In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.The efficacy and tolerability of rotigotine on patients with periodic limb movement in sleep: A systematic review and meta-analysis.Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's DiseaseIn vitro and in silico analysis of the effects of D receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrationsBinding kinetics of cariprazine and aripiprazole at the dopamine D receptor
P2860
Q27312273-96F236F5-64E7-40D8-BC9A-700B51764D77Q34524556-AF61CA38-5DA6-4D57-A635-27F49C600FADQ37383141-5B999D05-4DF5-47FF-A699-C1EEEE022DF9Q38662579-7CD2A923-6634-4A2C-89A6-22BE74824E03Q47430695-2406FE35-8988-4987-A033-3044F8B946A0Q47744210-58D071B8-E23F-49EB-962F-C0823AB2F69DQ47952336-428CC70A-47AF-4BDE-9D2E-23CEEDB898A9Q49438954-5638B4A5-CEB6-4207-84B4-BB55EE60D170Q50243244-9F5B40BA-DC5D-4A42-9363-EAD19E54FC72Q51740015-36D295F6-7EE5-4DAE-A34A-CD5F645ED32CQ55302709-2FBA1AEB-A575-437F-B720-9D749727350AQ58700802-EA7CA303-E2B7-4334-8EBF-C6D81DA89E27Q58703159-EAAC7C77-8D37-41A2-92EC-ECC5E10E4018Q58730805-FB556F87-4FEB-44AF-8D4F-CF8ABD44A2E4
P2860
Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@ast
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@en
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@nl
type
label
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@ast
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@en
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@nl
prefLabel
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@ast
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@en
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@nl
P2093
P2860
P3181
P356
P1476
Rotigotine is a potent agonist ...... t dopamine D2 and D3 receptors
@en
P2093
Dieter Scheller
Martyn Wood
Michel Gillard
P2860
P304
P3181
P356
10.1111/BPH.12988
P407
P577
2015-01-13T00:00:00Z